Thomas Gabrielczyk's articles Biotechnology Elevation Oncology Inc licences Synaffix BV’s ADC platform With the US$368m licence deal, Elevation Oncology, Inc is recognising Synaffix’s expertise in ADC development for the development of EO-1022. In contrast to Synaffix’s November deal with the Chinese BigHat Bioscience Co. Ltd, the US company does not book Lonza’s ADC manufacturing services that offers the same quality assurance process for all (clinicla) development phases, […] Written by Thomas Gabrielczyk December 13, 2024December 13, 2024 Saving Bookmark this article Bookmarked Biotechnology Tetraspecific B/NK cell better than T cell engagers The therapeutic landscape for relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) is evolving toward targeted T-cell based immunotherapies, including CD19-targeted CAR-T and CD3xCD20 T-cell engaging (TCE) bispecificantibodies. Yet, there remains an unmet medical need for patients who are refractory to, or ineligible for these treatments. Leveraging natural killer NK cells emerges as a promising […] Written by Thomas Gabrielczyk November 16, 2024November 16, 2024 Saving Bookmark this article Bookmarked Biotechnology Sphingotec secures Series C financing Diagnostics company SphingoTec GmbH (Hennigsdorf, Germany) has successful closed a €5m Series C financing round led by Think.Health Ventures, with support from existing investors Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners. The raised capital will allow the company to reach profitability through partnerships and licence deals of its kidney function test penKid and […] Written by Thomas Gabrielczyk August 15, 2024August 15, 2024 Saving Bookmark this article Bookmarked Biotechnology Gourmey files first EU application for cell-based meat At the time of its EU market authorisation application, Gourmey SAS, which has raised €57.8m so far, has applied for authorisation from the competent authorities in the UK, Switzerland, Singapore and the USA. Ivo Rzegotta, responsible for political communication at GFI Europe interest group, described the application as an important signal for the sector: ‘Cultivated […] Written by Thomas Gabrielczyk July 29, 2024July 29, 2024 Saving Bookmark this article Bookmarked
Biotechnology Elevation Oncology Inc licences Synaffix BV’s ADC platform With the US$368m licence deal, Elevation Oncology, Inc is recognising Synaffix’s expertise in ADC development for the development of EO-1022. In contrast to Synaffix’s November deal with the Chinese BigHat Bioscience Co. Ltd, the US company does not book Lonza’s ADC manufacturing services that offers the same quality assurance process for all (clinicla) development phases, […] Written by Thomas Gabrielczyk December 13, 2024December 13, 2024 Saving Bookmark this article Bookmarked
Biotechnology Tetraspecific B/NK cell better than T cell engagers The therapeutic landscape for relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) is evolving toward targeted T-cell based immunotherapies, including CD19-targeted CAR-T and CD3xCD20 T-cell engaging (TCE) bispecificantibodies. Yet, there remains an unmet medical need for patients who are refractory to, or ineligible for these treatments. Leveraging natural killer NK cells emerges as a promising […] Written by Thomas Gabrielczyk November 16, 2024November 16, 2024 Saving Bookmark this article Bookmarked
Biotechnology Sphingotec secures Series C financing Diagnostics company SphingoTec GmbH (Hennigsdorf, Germany) has successful closed a €5m Series C financing round led by Think.Health Ventures, with support from existing investors Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners. The raised capital will allow the company to reach profitability through partnerships and licence deals of its kidney function test penKid and […] Written by Thomas Gabrielczyk August 15, 2024August 15, 2024 Saving Bookmark this article Bookmarked
Biotechnology Gourmey files first EU application for cell-based meat At the time of its EU market authorisation application, Gourmey SAS, which has raised €57.8m so far, has applied for authorisation from the competent authorities in the UK, Switzerland, Singapore and the USA. Ivo Rzegotta, responsible for political communication at GFI Europe interest group, described the application as an important signal for the sector: ‘Cultivated […] Written by Thomas Gabrielczyk July 29, 2024July 29, 2024 Saving Bookmark this article Bookmarked
